Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer
Jaguar Health's subsidiary Napo Pharmaceuticals presented positive preliminary open-label pilot data for crofelemer in adult Type 1 short bowel syndrome patients with intestinal failure at ACG 2026 on October 13. Four of six planned subjects completed the 12-week protocol: two saw ostomy volume fall ~5%, one reduced parenteral support volume by 9%, and three improved urinary output by an average of 88%, sustained four weeks after stopping therapy, with no significant adverse events.
Key figures
- Drug Name
- crofelemer powder for oral solution
- Phase Of Trial
- open-label pilot study (Phase 2 RCT ongoing)
- Dosing
- 3 mg/kg/dose orally three times daily for 12 weeks
- Subjects planned
- 6
- Subjects completed
- 4
- Ps volume reduction pct
- 9% in one subject
- Ostomy volume reduction pct
- 5% average decrease at 12 weeks in two subjects
- Urinary output improvement pct
- 88% average improvement in three subjects
- Ostomy output rebound post cessation pct
- 23% average increase in three subjects
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.